Sales & Support: 314-485-5210



Catalogue number:
5 mg
Product is available in:
  • USA
  • Canada
$68.00 Shipping is calculated in checkout

Bromodomain (BET) inhibitor. SARS-CoV-2 transmembrane protein E binds to the bromodomain-containing proteins BRD2 and BRD4. Gordon et al. bioRxiv, Mar 23 2020, https://doi.org/10.1101/2020.03.22.002386.

  • Datasheet:   view or download
  • Applications:In clinical trials for other indication(s)
Product Type:

Biochemicals & reagents

CAS Number:



1) Picaud et al. (2013), RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain; Proc. Natl. Acad. Sci. USA, 110 19754 2) McLure et al. (2013), RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist; PLoS One, 8 e83190 3) Bailey et al. (2010), RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo; J. Am. Coll. Cardiol., 55 2580 4) Jahagirdar et al. (2014), A novel BET bromodomain inhibitor, RVX-208 shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice; Atherosclerosis, 236 91

Limit of Detection:


Storage Temperature:

-20°C (des.)

Additional Information:

RVX-208 is a potent BET bromodomain antagonist with IC50 of 0.510 μM for BD2, with approximately 170-fold selectivity over BD1 (1,2). This compound increases apolipoprotein A-1 and HDL cholesterol in vitro and in vivo (3) and reduces atherosclerosis (4).